Loading…
Loading…
EQUITY / NASDAQ · XNCM
Virax Biolabs Group Ltd.
No accepted understanding yet. Follow this company to establish research where evidence supports it.
Open research workspace →04/01/2024 – 03/31/2025 · USD · Units
Reported figures establish facts for this period; they do not by themselves establish a profitability trend.
Open report ↗2.4 USD · 0%
Observed: Oct 5, 2026, 11:59 PM · TickerLayer indicative price; may be delayed
Powered by TickerLayer
10/05/2026 · 2.4 USD · Volume 2,895,139
251 actual observations · Latest bar: 2026-10-05 · Market data is indicative; provider terms apply.
3 available financial reports
Research reports →SEC FINANCIAL REPORTS
04/01/2024 – 03/31/2025 · Units
| Metric | 2025 / Year end | 2024 / Year end | Change |
|---|---|---|---|
| Revenue | 6,331 USD | 156,419 USD | -95.95% |
| Operating profit | -6,162,897 USD | -6,496,473 USD | — |
| Net income | -6,067,232 USD | -6,739,120 USD | — |
| Operating cash flow | -4,563,576 USD | -6,247,016 USD | — |
| Cash and cash equivalents | 4,228,944 USD | 3,589,244 USD | +17.82% |
Changes are calculated only for matching period length, consolidation, currency, and scale. Percentages are not shown for zero or negative baselines.
Each column uses its report's scale. Check column headers before comparing different consolidation scopes and scales.
| Financial metric | 2025 / Year end04/01/2024 – 03/31/2025ConsolidatedUnits · USD | 2024 / Year end04/01/2023 – 03/31/2024ConsolidatedUnits · USD | 2023 / Year end04/01/2022 – 03/31/2023ConsolidatedUnits · USD |
|---|---|---|---|
| Cash and cash equivalentsBalance sheet | 4,228,944 USD | 3,589,244 USD | 9,352,538 USD |
| Financing cash flowCash flow statement | 5,807,166 USD | 1,648,171 USD | 13,688,952 USD |
| Gross profitIncome statement | -53,067 USD | 50,590 USD | -1,365 USD |
| Investing cash flowCash flow statement | -603,890 USD | -1,164,449 USD | -178,403 USD |
| Net incomeIncome statement | -6,067,232 USD | -6,739,120 USD | -5,457,763 USD |
| Operating cash flowCash flow statement | -4,563,576 USD | -6,247,016 USD | -4,179,767 USD |
| Operating profitIncome statement | -6,162,897 USD | -6,496,473 USD | -5,732,761 USD |
| RevenueIncome statement | 6,331 USD | 156,419 USD | 8,561 USD |
| Total assetsBalance sheet | 6,426,903 USD | 5,483,969 USD | — |
| Total equityBalance sheet | 5,462,153 USD | 5,138,775 USD | 8,904,015 USD |
| Total liabilitiesBalance sheet | 964,750 USD | 345,194 USD | — |
| Report source | Open report ↗ Published: 07/02/2025 | Open report ↗ Published: 07/02/2025 | Open report ↗ Published: 07/02/2025 |
The latest available source version is shown for each period. Previous versions and correction relationships are not shown in this view.